Why the study?
AF is associated with residual thromboembolic risk despite anticoagulation, and the prognostic value of remnant cholesterol and its discordance with LDL-C in this population remained unclear.
Do elevated remnant cholesterol levels increase the risk of thromboembolic events in anticoagulated patients with atrial fibrillation?
Do elevated remnant cholesterol levels increase the risk of thromboembolic events in anticoagulated patients with atrial fibrillation?
Elevated remnant cholesterol is independently associated with a higher thromboembolic risk in anticoagulated AF patients with low LDL-C, highlighting its value in residual risk stratification.
Answers are grounded in this paper and cite their sources.
May aid residual risk stratification in anticoagulated AF with low LDL-C; hypothesis-generating and requires prospective validation.
BACKGROUND: Remnant cholesterol (RC) has emerged as an independent contributor to residual cardiovascular risk, beyond low-density lipoprotein cholesterol (LDL-C). As atrial fibrillation (AF) is a common arrhythmia associated with increased thromboembolic risk even despite anticoagulation, we assessed the prognostic value of RC in AF, with a particular focus on its association with LDL-C discordance. METHODS: In this prospective cohort study, AF outpatients initiating oral anticoagulation between January 2016 and November 2021 were enrolled. Baseline LDL-C and RC levels were measured, and patients were stratified into four groups based on these values. The primary outcome was a composite of thromboembolic events; secondary outcomes included major adverse cardiovascular events (MACE), cardiovascular death, and all-cause death. Associations between RC levels and clinical outcomes across LDL-C strata were assessed using multivariable Cox proportional hazards models and as a continuous variable using restricted cubic spline (RCS) analyses. RESULTS: Among 1,694 patients (52.5% female; median age 76 years (IQR 69-82); mean follow-up: 1.86 years, SD 0.4 years), 5.7% (97) experienced incident thromboembolic events. In the low LDL-C group, RCS analysis showed a significant linear association between RC levels and thromboembolic risk (p-overall = 0.044). High RC levels were independently associated with an increased risk of thromboembolic events compared to the low RC subgroup (aHR 1.82; 95% CI, 1.03-3.23; p = 0.039), but this was nonsignificant in the high LDL-C group. For secondary outcomes, higher RC levels were not significantly associated with increased adverse event risk in either LDL-C group. CONCLUSION: Despite low LDL-C levels in AF patients, elevated RC levels were still independently associated with a higher thromboembolic risk, suggesting discordance between RC and LDL-C in risk stratification among patients with AF.
No takes yet. Share an insight, caveat, or question.
Soler‐Espejo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: